Bajaj Finserv Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare Total Return Index (TRI)) is not available to us as a series.
Up to one year: absolute. Longer: annualised. Category = median of Sectoral/Thematic regular-plan Growth funds; index = NIFTY 500 TRI.
| Period | This fund | Category median | NIFTY 500 TRI | Rank in category |
|---|---|---|---|---|
| 1 month | -4.37% | -5.49% | -6.32% | — |
| 3 months | +5.24% | -3.18% | -5.14% | — |
| 6 months | +25.08% | +8.25% | +5.07% | — |
| 1 year | +18.98% | +0.08% | -3.80% | #13 of 224 Top 6% |
| 3 years | — | +11.62% | +9.14% | — |
| 5 years | — | +10.24% | +8.89% | — |
| 10 years | — | +13.33% | +12.66% | — |
| Since launch of NAV data | +7.23% | — | — | — |
| Window | High | Low |
|---|---|---|
| 1 month | 12.0780 | 11.3910 |
| 3 months | 12.0780 | 10.8240 |
| 6 months | 12.0780 | 9.0380 |
| 1 year | 12.0780 | 8.9650 |
A period is a dash when the fund has not existed that long or its NAV history has a hole at the start date — never a partial figure.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | |
|---|---|---|---|---|---|---|---|
| This fund | — | — | — | — | — | -4.58% | +18.23% |
| Category median | +13.70% | +30.80% | +4.16% | +31.15% | +20.64% | +3.12% | -2.81% |
| NIFTY 500 TRI | +17.89% | +31.60% | +4.25% | +26.91% | +16.24% | +7.76% | -7.72% |
Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare Total Return Index (TRI)) is not available to us as a series.
Twenty checks of five points each: performance, portfolio, operations, and risk against reward. Only checks we have data for are counted.
Risk-free rate 6.06% (3-year annualised return of the NSE 1-day (overnight) rate index). Benchmark-relative ratios use NIFTY 500 TRI. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare Total Return Index (TRI)) is not available to us as a series.
| Ratio | This fund | Category median | Against category |
|---|---|---|---|
| Sharpe ratio | — | 0.35 | — |
| Sortino ratio | — | 0.47 | — |
| Standard deviation | — | 15.72% | — |
| Maximum drawdown | — | -21.95% | — |
| Beta | — | 0.93 | — |
| R-squared | — | 82.6% | — |
| Jensen's alpha | — | 2.05% | — |
| Treynor ratio | — | 5.52 | — |
| Information ratio | — | 0.33 | — |
| Upside capture | — | 93.1% | — |
| Downside capture | — | 91.6% | — |
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Divi's Laboratories Limited | Healthcare | 10.55% | — | 83.0 |
| Sun Pharmaceutical Industries Limited | Healthcare | 8.21% | — | 143.5 |
| Rubicon Research Limited | Healthcare | 6.81% | — | 111.0 |
| Piramal Pharma Limited | Healthcare | 6.72% | — | 37.0 |
| Aurobindo Pharma Limited | Healthcare | 6.18% | — | 37.5 |
| Apollo Hospitals Enterprise Limited | Healthcare | 6.00% | — | 73.1 |
| Torrent Pharmaceuticals Limited | Healthcare | 5.03% | — | 77.7 |
| Neuland Laboratories Limited | Healthcare | 4.11% | — | 56.5 |
| Emcure Pharmaceuticals Limited | Healthcare | 3.84% | — | 45.3 |
| Max Healthcare Institute Limited | Healthcare | 3.35% | — | 124.3 |
| Fortis Healthcare Limited | Healthcare | 2.69% | — | 255.5 |
| Zydus Lifesciences Limited | Healthcare | 2.56% | — | 32.6 |
| IPCA Laboratories Limited | Healthcare | 2.46% | — | 39.8 |
| Laurus Labs Limited | Healthcare | 2.36% | — | 122.0 |
| Vijaya Diagnostic Centre Limited | Healthcare | 2.31% | — | 75.9 |
| Zydus Wellness Limited | Fast Moving Consumer Goods | 2.27% | — | 399.8 |
| Senores Pharmaceuticals Limited | Healthcare | 2.15% | — | 242.9 |
| Clearing Corporation of India Ltd | — | 2.12% | — | — |
| Shaily Engineering Plastics Limited | Consumer Durables | 2.00% | — | 110.5 |
| GlaxoSmithKline Pharmaceuticals Limited | Healthcare | 1.79% | — | 43.8 |
| Glenmark Pharmaceuticals Limited | Healthcare | 1.70% | — | 316.1 |
| Dr. Lal Path Labs Limited | Healthcare | 1.68% | — | 38.4 |
| Sanofi Consumer Healthcare India Limited | Healthcare | 1.41% | — | 32.5 |
| Cipla Limited | Healthcare | 1.39% | — | 35.1 |
| Bajaj Finserv Money Market Fund-Direct Plan-Growth | — | 1.30% | — | — |
| Dr. Reddy's Laboratories Limited | Healthcare | 1.28% | — | 150.9 |
| Biocon Limited | Healthcare | 1.16% | — | 596.5 |
| Navin Fluorine International Limited | Chemicals | 0.99% | — | 74.9 |
| Krishna Institute Of Medical Sciences Limited | Healthcare | 0.93% | — | 105.1 |
| Turtlemint Fintech Solutions Limited | Financial Services | 0.92% | — | — |
| Medi Assist Healthcare Services Limited | Financial Services | 0.82% | — | 38.1 |
| Onesource Specialty Pharma Limited | Healthcare | 0.82% | — | 358.6 |
| Jubilant Pharmova Limited | Healthcare | 0.76% | — | 677.0 |
| Net Receivables / (Payables) | — | 0.61% | — | — |
| MTAR Technologies Limited | Capital Goods | 0.26% | — | 174.9 |
| Sumitomo Chemical India Limited | Chemicals | 0.25% | — | 35.7 |
| Neogen Chemicals Limited | Chemicals | 0.21% | — | 118.2 |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 2.37% · Nov 25 2.37% · Dec 25 2.37% · Jan 26 2.39% · Feb 26 2.39% · Mar 26 2.39% · Apr 26 2.46% · May 26 2.46% · Jun 26 2.61% · Jul 26 2.56% · Aug 26 2.59% · Sep 26 2.59%
Entry load – Nil; Exit load – For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP) and Systematic Transfer Plan (STP), exit load will be as follows:; • if units are redeemed / switched out within 3 months from the date of allotment: 1% of applicable NAV.; • if units are redeemed/switched out after 3 months from the date of allotment, no exit load is payable.; The Scheme will not levy exit load in case the timelines for rebalancing portfolio as stated in SEBI Master Circular for Mutual Funds dated June 27, 2024, is not complied with.; The Trustee / AMC reserves the right to change the load structure any time in the future if they so deem fit on a prospective basis. The investor is requested to check the prevailing load structure of the scheme before investing.
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.; However, there is no assurance that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
